Janwillem Naesens Buys $5M of Cyteir Therapeutics Inc (CYT) — SEC Form 4, Jun 24, 2021

Open-Market Net Purchase · SEC Form 4
+$4,999,986
Reporting Owner
Janwillem Naesens
Director
TXN 2021-06-22 · FILED 2021-06-24
Equity Position 3.54M sh 0 → 3,536,803
Filing Lag 2 business days within 2-day SEC deadline
Form 4 · Statement of Changes in Beneficial Ownership

Cyteir Therapeutics Inc

CYT CIK 0001662244
All Cyteir Therapeutics Inc insider activity
Filing Date
2021-06-24
Report Date
2021-06-22
Accession No.
0000899243-21-025824
Accepted At
2021-06-24 20:50 UTC
Reporting Owner
Name Relationship
Janwillem Naesens CIK 0001864377
Director
Janwillem Naesens at Cyteir Therapeutics Inc Full insider history
Bought (12 mo) —
Sold (12 mo) —
More from this insider at Cyteir Therapeutics Inc
2022-02-24 Award — View
2021-06-24 Buy +$4,999,986 View
All filings by this insider at Cyteir Therapeutics Inc
Non-Derivative Securities Transactions
Title Date Type Shares Price Net Total Post-Txn Ownership
Common StockF1F2 2021-06-22 C - Conversion 3,259,026 A — 3,259,026 Indirect
Common StockF2 2021-06-22 P - Purchase 277,777 A $18.00 +$4,999,986 3,536,803 Indirect
Derivative Securities Transactions
Title Strike Date Type Shares Price Expiration Underlying Ownership
Series B Convertible Preferred StockF1F1F1F1F2 2021-06-22 C - Conversion 10,000,000 D 2,933,583 Common Stock Indirect
Series C Convertible Preferred StockF1F1F1F1F2 2021-06-22 C - Conversion 1,109,368 D 325,443 Common Stock Indirect
Footnotes (2)
F1
Each share of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock converted into shares of Common Stock at a ratio of 3.4088:1 upon completion of the Issuer's initial public offering. The shares have no expiration date. Show more
F2
Shares held by Droia Invest II SCSp. DF II GP Sarl is the general partner of Droia Invest II SCSp. Wepaven BV (represented by the Reporting Person) and IHL SA (represented by Luc Verelst), the managers of DF II GP Sarl, share voting and investment power with respect to the shares held of record by Droia Invest II SCSp. The Reporting Person, along with Mr. Verelst, disclaim beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein. Show more

Related filings at Cyteir Therapeutics Inc

Institutional Holders
13F holders · Mar 31, 2024 4 institutional managers reporting a position
Largest by reported value
  1. Bml Capital Management, Llc $11M
  2. Acadian Asset Management Llc $77K
  3. Boston Family Office Llc $73K
Other insiders at Cyteir Therapeutics Inc
All Cyteir Therapeutics Inc insider activity
GET /v1/forms/4/0000899243-21-025824 API docs
View Original SEC Filing